Molecular Imaging of Cancer Cachexia
Molecular Imaging of Cancer Cachexia
批准号:
7706409
负责人:
Zaver M. Bhujwalla
金额:
$21.65万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-07-01 至 2011-06-30
关键词:
AccountingArtsBody Weight decreasedCachexiaCancer PatientCarbohydratesCessation of lifeCharacteristicsDevelopmentDiseaseEarly DiagnosisEatingEventExhibitsFatigueFunctional ImagingFutureHistologicImageImaging TechniquesInflammatoryLifeLipidsMalignant NeoplasmsMedicineMetabolicModalityModelingMolecularMolecular TargetMuscle ProteinsNatureNeoplasm MetastasisNormal tissue morphologyOrganOrgan failurePathway interactionsPatientsPre-Clinical ModelQuality of lifeRoleScienceSkeletal MuscleSmall Interfering RNASocietiesStagingSuppressor GenesTherapeuticTranslatingTreatment outcomeTumor Suppressor GenesUnited Statescytokineindexinginsightmolecular imagingmortalitypre-clinicalpreclinical studyprotein metabolismpublic health relevanceresponsetumortumor progression
中文摘要
描述(由申请人提供):癌症的最未被探索的但仍具有破坏性的后果之一是恶病质,其中身体被紊乱的碳水化合物、脂质和蛋白质代谢消耗的状况,所述紊乱的碳水化合物、脂质和蛋白质代谢由全身分泌的炎性细胞因子和肿瘤诱导。 恶病质是所有癌症相关死亡的20-40%的原因。 在3至6个月内体重减轻5%与治疗效果差,疲劳和生活质量差有关,体重减轻30%通常是致命的。 逆转或控制这种疾病的能力将对治疗结果、生活质量和死亡率产生巨大影响,但迄今为止,这种疾病还没有已知的治愈方法。 由于这种疾病的多因素特征,很难理解肿瘤对身体器官的影响,以及导致这种致命疾病的事件顺序。 这些见解对于确定治疗策略至关重要,特别是在分子靶向医学的这十年中。 了解肿瘤和正常组织之间的相互作用,并非侵入性地成像这种情况的发展顺序的能力将是非常宝贵的,在确定关键阶段时,条件变得危及生命。 目前的多模态分子和功能成像能力提供了独特的机会,研究恶病质整体在临床前模型和临床。 在这一探索性应用中,我们将使用最先进的成像技术结合分子表征来了解癌症诱导的恶病质和临床前模型中的恶病质级联反应。 在这些临床前研究中确定的成像指标可以在未来被转化为检测患者恶病质级联的发展。 根据确定的代谢靶点,图像引导的siRNA递送可用于未来的研究,以下调通路并了解其对恶病质级联的影响。 公共卫生相关性:由癌症引起的恶病质是癌症的最未被探索的和破坏性的后果之一,并且是所有癌症相关死亡的20-40%的原因。 恶病质引起的体重减轻5%超过3至6个月与治疗效果差,疲劳和生活质量差有关,体重减轻30%通常是致命的。 逆转或控制这种疾病的能力将对治疗结果、生活质量和死亡率产生巨大影响,但迄今为止,这种疾病还没有已知的治愈方法。 在这一探索性应用中,我们将使用最先进的成像技术与分子表征相结合,以了解临床前肿瘤模型中癌症诱导的恶病质和恶病质级联反应。
英文摘要
DESCRIPTION (provided by applicant): One of the most under explored and yet devastating consequences of cancer is cachexia, a condition in which the body is consumed by deranged carbohydrate, lipid and protein metabolism induced by inflammatory cytokines secreted systemically, and by the tumor. Cachexia is the cause for 20-40% of all cancer related deaths. A weight loss of 5% over 3 to 6 months is associated with poor treatment outcome, fatigue and poor quality of life, and a weight loss of 30% is frequently lethal. The ability to reverse or control this condition would have a tremendous impact on treatment outcome, quality of life, and mortality, but to date there are no known cures for this condition. Because of the multi-factorial characteristics of this condition, it has been difficult to understand the impact of the tumor on body organs, and the sequence of events that leads to this lethal condition. Such insights are critically important in identifying therapeutic strategies, especially in this decade of molecular targeted medicine. The ability to understand the interaction between the tumor and normal tissues and noninvasively image the sequence of development of this condition would be invaluable in identifying critical stages when the condition becomes life-threatening. Current multi-modality molecular and functional imaging capabilities provide unique opportunities to study cachexia holistically in preclinical models and clinically. In this exploratory application, we will use state-of-the art imaging techniques in combination with molecular characterization to understand cancer-induced cachexia and the cachexia cascade in preclinical models. Imaging indices identified in these preclinical studies can, in the future, be translated to detect the development of the cachexia cascade in patients. Depending on the metabolic targets identified, image-guided siRNA delivery can be used in future studies to down-regulate pathways and understand their impact on the cachexia cascade. PUBLIC HEALTH RELEVANCE: Cachexia induced by cancer is one of the most under explored and yet devastating consequences of cancer, and is the cause for 20-40% of all cancer related deaths. Cachexia-induced weight loss of 5% over 3 to 6 months is associated with poor treatment outcome, fatigue and poor quality of life, and a weight loss of 30% is frequently lethal. The ability to reverse or control this condition would have a tremendous impact on treatment outcome, quality of life, and mortality, but to date there are no known cures for this condition. In this exploratory application, we will use state-of-the art imaging techniques in combination with molecular characterization to understand cancer-induced cachexia and the cachexia cascade in preclinical tumor models.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Tumor Microenvironment in Nanoparticle Delivery and Function
-
批准号:10059035
-
项目类别:
-
资助金额:$37.46万
-
财政年份:2020
-
负责人:Zaver M. Bhujwalla
-
依托单位:
The Tumor Microenvironment in Nanoparticle Delivery and Function
-
批准号:10405098
-
项目类别:
-
资助金额:$36.71万
-
财政年份:2020
-
负责人:Zaver M. Bhujwalla
-
依托单位:
The Tumor Microenvironment in Nanoparticle Delivery and Function
-
批准号:10170305
-
项目类别:
-
资助金额:$37.46万
-
财政年份:2020
-
负责人:Zaver M. Bhujwalla
-
依托单位:
The Tumor Microenvironment in Nanoparticle Delivery and Function
-
批准号:10617333
-
项目类别:
-
资助金额:$36.71万
-
财政年份:2020
-
负责人:Zaver M. Bhujwalla
-
依托单位:
Molecular Imaging and Theranostics of Cancer
-
批准号:10242814
-
项目类别:
-
资助金额:$98.23万
-
财政年份:2017
-
负责人:Zaver M. Bhujwalla
-
依托单位:
Molecular Imaging and Theranostics of Cancer
-
批准号:10693873
-
项目类别:
-
资助金额:$96.24万
-
财政年份:2017
-
负责人:Zaver M. Bhujwalla
-
依托单位:
Molecular Imaging Reagents for Prostate Cancer Theranostics
-
批准号:10226208
-
项目类别:
-
资助金额:$23.65万
-
财政年份:2017
-
负责人:Zaver M. Bhujwalla
-
依托单位:
Molecular Imaging and Theranostics of Cancer
-
批准号:10455724
-
项目类别:
-
资助金额:$96.24万
-
财政年份:2017
-
负责人:Zaver M. Bhujwalla
-
依托单位:
Molecular Imaging of Cachexia in Pancreatic Cancer
-
批准号:9026680
-
项目类别:
-
资助金额:$37.06万
-
财政年份:2015
-
负责人:Zaver M. Bhujwalla
-
依托单位:
Decoy nanoparticles to disrupt cancer cell-stromal cell networks
-
批准号:9102034
-
项目类别:
-
资助金额:$21.14万
-
财政年份:2015
-
负责人:Zaver M. Bhujwalla
-
依托单位:
Imaging Hypoxia and Cancer Stem Cells
-
批准号:8078137
-
项目类别:
-
资助金额:$33.01万
-
财政年份:2009
-
负责人:Zaver M. Bhujwalla
-
依托单位:
Imaging Permissive Microenvironmental Niches for Cancer Stem Cells
-
批准号:7747958
-
项目类别:
-
资助金额:$21.65万
-
财政年份:2009
-
负责人:Zaver M. Bhujwalla
-
依托单位:
Imaging Hypoxia and Cancer Stem Cells
-
批准号:8475432
-
项目类别:
-
资助金额:$31.03万
-
财政年份:2009
-
负责人:Zaver M. Bhujwalla
-
依托单位:
Image-guided Prodrug and siRNA Targeting of Cancer
-
批准号:8063195
-
项目类别:
-
资助金额:$33.01万
-
财政年份:2009
-
负责人:Zaver M. Bhujwalla
-
依托单位:
Imaging Hypoxia and Cancer Stem Cells
-
批准号:8277335
-
项目类别:
-
资助金额:$33.01万
-
财政年份:2009
-
负责人:Zaver M. Bhujwalla
-
依托单位:
Imaging Hypoxia and Cancer Stem Cells
-
批准号:9292286
-
项目类别:
-
资助金额:$38.48万
-
财政年份:2009
-
负责人:Zaver M. Bhujwalla
-
依托单位:
Image-guided Prodrug and siRNA Targeting of Cancer
-
批准号:8468126
-
项目类别:
-
资助金额:$31.03万
-
财政年份:2009
-
负责人:Zaver M. Bhujwalla
-
依托单位:
Imaging Permissive Microenvironmental Niches for Cancer Stem Cells
-
批准号:7587197
-
项目类别:
-
资助金额:$18.04万
-
财政年份:2009
-
负责人:Zaver M. Bhujwalla
-
依托单位:
Imaging Hypoxia and Cancer Stem Cells
-
批准号:7737618
-
项目类别:
-
资助金额:$34.03万
-
财政年份:2009
-
负责人:Zaver M. Bhujwalla
-
依托单位:
Image-guided Prodrug and siRNA Targeting of Cancer
-
批准号:7729911
-
项目类别:
-
资助金额:$34.03万
-
财政年份:2009
-
负责人:Zaver M. Bhujwalla
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Handbook of the Mathematics of the Arts and Sciences的中文翻译
-
批准号:12226504
-
项目类别:数学天元基金项目
-
资助金额:20.0万元
-
批准年份:2022
-
负责人:黄朝凌
-
依托单位:
ARTS在邻苯二甲酸(2-乙基己基)酯诱导的小鼠睾丸间质细胞凋亡中的作用及机理研究
-
批准号:--
-
项目类别:--
-
资助金额:35万元
-
批准年份:2020
-
负责人:陈加祥
-
依托单位:
ARTS在邻苯二甲酸(2-乙基己基)酯诱导的小鼠睾丸间质细胞凋亡中的作用及机理研究
-
批准号:82060278
-
项目类别:地区科学基金项目
-
资助金额:35.0万元
-
批准年份:2020
-
负责人:陈加祥
-
依托单位:
促进肿瘤凋亡的融合蛋白CPP-TRAIL-ARTS C27的制备及机制研究
-
批准号:81372444
-
项目类别:面上项目
-
资助金额:70.0万元
-
批准年份:2013
-
负责人:易成
-
依托单位:
雄性锹甲的生殖对策抉择ARTs及其进化机制-基于行为与SSRs标记的整合研究
-
批准号:31201745
-
项目类别:青年科学基金项目
-
资助金额:25.0万元
-
批准年份:2012
-
负责人:万霞
-
依托单位: